Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

Publisher： Bentham Science Publishers

E-ISSN： 1875-6190|12|5|387-398

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.12, Iss.5, 2014-09, pp. : 387-398

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agomelatine for the treatment of major depressive disorder

By Carney Regina M   Shelton Richard C  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2411-2419

Informa Healthcare

Access to resources Recommend Favorite

Agomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness

By Kennedy Sidney H.   Rizvi Sakina J.  

CNS Drugs, Vol. 24, Iss. 6, 2010-06 ,pp. : 479-499

Adis International

Access to resources Recommend Favorite

Agomelatine: a guide to its use in major depressive disorder

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 2, 2010-02 ,pp. : 6-9

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

By Howland Robert H.  

Drug Safety, Vol. 34, Iss. 9, 2011-09 ,pp. : 709-731

Adis International

Access to resources Recommend Favorite

The risks and benefits of antidepressant use in patients with major depressive disorder (MDD) have been highlighted

By  

Reactions Weekly, Vol. 1, Iss. 1025, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite